Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Apr 15;144(8):1962-1974.
doi: 10.1002/ijc.31921. Epub 2018 Nov 13.

Familial breast cancer and DNA repair genes: Insights into known and novel susceptibility genes from the GENESIS study, and implications for multigene panel testing

Elodie Girard  1   2   3   4 Séverine Eon-Marchais  1   2   3   4 Robert Olaso  5 Anne-Laure Renault  1   2   3   4 Francesca Damiola  6 Marie-Gabrielle Dondon  1   2   3   4 Laure Barjhoux  6 Didier Goidin  7 Vincent Meyer  5 Dorothée Le Gal  1   2   3   4 Juana Beauvallet  1   2   3   4 Noura Mebirouk  1   2   3   4 Christine Lonjou  1   2   3   4 Juliette Coignard  1   2   3   4   8 Morgane Marcou  1   2   3   4 Eve Cavaciuti  1   2   3   4 Céline Baulard  5 Marie-Thérèse Bihoreau  5 Odile Cohen-Haguenauer  9 Dominique Leroux  10 Clotilde Penet  11 Sandra Fert-Ferrer  12 Chrystelle Colas  13   14 Thierry Frebourg  15 François Eisinger  16 Claude Adenis  17 Anne Fajac  18 Laurence Gladieff  19 Julie Tinat  15 Anne Floquet  20 Jean Chiesa  21 Sophie Giraud  22 Isabelle Mortemousque  23 Florent Soubrier  24 Séverine Audebert-Bellanger  25 Jean-Marc Limacher  26 Christine Lasset  27 Sophie Lejeune-Dumoulin  28 Hélène Dreyfus  29 Yves-Jean Bignon  30 Michel Longy  20 Pascal Pujol  31 Laurence Venat-Bouvet  32 Valérie Bonadona  27 Pascaline Berthet  33 Elisabeth Luporsi  34 Christine M Maugard  35 Catherine Noguès  16 Capucine Delnatte  36 Jean-Pierre Fricker  37 Paul Gesta  38 Laurence Faivre  39 Alain Lortholary  40 Bruno Buecher  14 Olivier Caron  41 Marion Gauthier-Villars  14 Isabelle Coupier  31 Nicolas Servant  1   2   3   4 Anne Boland  5 Sylvie Mazoyer  42 Jean-François Deleuze  5 Dominique Stoppa-Lyonnet  14   43   44 Nadine Andrieu  1   2   3   4 Fabienne Lesueur  1   2   3   4
Affiliations

Familial breast cancer and DNA repair genes: Insights into known and novel susceptibility genes from the GENESIS study, and implications for multigene panel testing

Elodie Girard et al. Int J Cancer. .

Abstract

Pathogenic variants in BRCA1 and BRCA2 only explain the underlying genetic cause of about 10% of hereditary breast and ovarian cancer families. Because of cost-effectiveness, multigene panel testing is often performed even if the clinical utility of testing most of the genes remains questionable. The purpose of our study was to assess the contribution of rare, deleterious-predicted variants in DNA repair genes in familial breast cancer (BC) in a well-characterized and homogeneous population. We analyzed 113 DNA repair genes selected from either an exome sequencing or a candidate gene approach in the GENESIS study, which includes familial BC cases with no BRCA1 or BRCA2 mutation and having a sister with BC (N = 1,207), and general population controls (N = 1,199). Sequencing data were filtered for rare loss-of-function variants (LoF) and likely deleterious missense variants (MV). We confirmed associations between LoF and MV in PALB2, ATM and CHEK2 and BC occurrence. We also identified for the first time associations between FANCI, MAST1, POLH and RTEL1 and BC susceptibility. Unlike other associated genes, carriers of an ATM LoF had a significantly higher risk of developing BC than carriers of an ATM MV (ORLoF = 17.4 vs. ORMV = 1.6; p Het = 0.002). Hence, our approach allowed us to specify BC relative risks associated with deleterious-predicted variants in PALB2, ATM and CHEK2 and to add MAST1, POLH, RTEL1 and FANCI to the list of DNA repair genes possibly involved in BC susceptibility. We also highlight that different types of variants within the same gene can lead to different risk estimates.

Keywords: breast cancer; case-control study; exome sequencing; multigene panel testing; variant.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Strategy for genes prioritization. aThe DNA repair genes list was compiled from ACSN maps (https://acsn.curie.fr/), KEGG (http://www.genome.jp/kegg/pathway.html) and after review of literature.
Figure 2
Figure 2
Result of the association tests per variant type for the 113 genes. Legend: *, no LoF identified in cases and/or in controls; **, no LoF and no likely deleterious MV identified in cases and/or in controls.

References

    1. Collaborative Group on Hormonal Factors in Breast C . Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet 1996;347:1713–27. - PubMed
    1. Antoniou AC, Cunningham AP, Peto J, et al. The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. Br J Cancer 2008;98:1457–66. - PMC - PubMed
    1. Gadzicki D, Evans DG, Harris H, et al. Genetic testing for familial/hereditary breast cancer‐comparison of guidelines and recommendations from the UK, France, The Netherlands and Germany. J Community Genet 2011;2:53–69. - PMC - PubMed
    1. Thompson ER, Rowley SM, Li N, et al. Panel testing for familial breast cancer: calibrating the tension between research and clinical care. J Clin Oncol 2016;34:1455–9. - PubMed
    1. Southey MC, Teo ZL, Dowty JG, et al. A PALB2 mutation associated with high risk of breast cancer. Breast Cancer Res 2010;12:R109. - PMC - PubMed

Publication types

Supplementary concepts